Table 1 Demographic and clinicopathologic characteristics of all patients with CRLM undergoing R0 and R1 resection before and after 2:1 propensity score matching (n = 368)

Age (years, mean)

58.8 ± 11.2

56.7 ± 9.9

0.168

58.0 ± 10.2

57.0 ± 9.8

0.547

Sex (M/F)

199 (65.5)/105 (34.5)

43 (67.2)/21 (32.8)

0.791

82 (68.9)/37 (31.1)

43 (69.4)/19 (30.6)

0.951

BMI (kg/m²)

23.2 ± 2.9

23.2 ± 3.1

0.943

23.2 ± 3.1

23.1 ± 3.1

0.126

Primary CRC

 Primary CRC location (Rt colon/Lt colon/rectum)

55 (18.1)/123 (78.8)/126 (41.4)

7 (10.9)/33 (51.6)/24 (37.5)

0.188

24 (20.2)/54 (45.4) /41 (34.5)

7 (11.3)/31 (17.1) /24 (38.7)

0.322

 Primary CRC grade (WD/MD/PD)

15 (5.0)/275 (91.1)/12(4.0)

3 (4.7)/58 (90.6)/3(4.7)

0.933

7 (5.9)/109 (91.6)/3 (2.5)

3 (4.8)/56 (90.3)/3 (4.8)

0.644

 Primary CRC T stage^b (T1–2/T3–4)

20 (6.8) /273 (93.2)

7 (11.5)/54 (88.5)

0.285

7 (6.1)/108 (93.9)

7 (11.9)/52 (88.1)

0.239

 Primary CRC N stage (N0/N +)

87 (28.6)/21 7 (71.4)

20 (31.3)/44 (68.8)

0.673

37 (31.1)/82 (68.9)

18 (29.0)/44 (71.0)

0.775

 KRAS mutation (wild type/mutant)^c

116 (65.2)/62 (34.8)

27 (65.9)/14 (34.1)

0.934

49 (67.1)/24 (32.9)

26 (65.0)/14 (35.0)

0.819

 CRC R1 status

17 (5.6)

3 (4.3)

1.000

6 (5.0)

3 (4.8)

1.000

Hepatic lesion

 Size (cm, mean)

2.5 ± 1.9

3.0 ± 2.3

0.058

2.6 ± 2.1

2.8 ± 1.9

0.513

 Tumor size ≥ 5 cm

29 (9.5)

8 (12.5)

0.474

14 (11.8)

6 (9.7)

0.671

 No. liver metastasis (≤ 3/ ≥ 4)

221 (72.7)/83 (27.3)

32 (50.0)/ 32 (50.0)

< 0.001

63 (52.9)/56 (47.1)

32 (51.6)/30 (48.4)

0.865

 Initial CEA (≤ 50/ > 50)

221 (73.4)/80 (26.6)

42 (65.6)/22 (34.4)

0.207

79 (66.4)/40 (33.6)

42 (67.7)/20 (32.3)

0.854

 TBS (mean)

4.4 ± 3.4

5.8 ± 3.4

0.003

5.8 ± 4.2

5.6 ± 3.4

0.790

 TBS zone (1/2/3)

90 (29.6)/189 (62.2)/25 (8.2)

9 (14.1)/45 (70.3)/10 (15.6)

0.015

22 (18.5)/79 (66.4)/18 (15.1)

9 (4.5)/44 (71.0)/9 (14.5)

0.774

 Bilobar disease

118 (38.8)

43 (67.2)

< 0.001

76 (63.9)

41 (66.1)

0.762

 Necrosis ≥ 20%^a (n = 308)

141 (55.5)

28 (51.9)

0.624

59 (57.3)

27 (51.9)

0.526

 Non-tumor histology

  Normal

164 (53.9)

35 (54.7)

0.840

57 (47.9)

35 (56.5)

0.722

  Steatosis

98 (32.2)

19 (29.7)

38 (31.9)

17 (27.4)

  Steatohepatitis

14 (4.6)

2 (3.1)

7 (5.9)

2 (3.2)

  Sinusoidal obstruction syndrome

28 (9.2)

8 (12.5)

17 (14.3)

8 (12.9)

 Minor/major liver resection

193 (63.5)/111 (36.5)

44 (68.8)/20 (31.3)

0.424

74 (62.2)/45 (37.8)

43 (69.4)/19 (30.6)

0.338

 Intraoperative RFA

49 (16.1)

13 (20.3)

0.415

32 (26.9)

12 (19.4)

0.262

 Intraoperative transfusion

57 (18.8)

22 (34.4)

0.006

34 (28.6)

20 (32.3)

0.607

Preoperative chemotherapy

147 (48.4)

38 (59.4)

0.109

73 (61.3)

36 (58.1)

0.669

Preoperative target therapy (bevacizumab/cetuximab)

43 (14.1) /34 (11.2)

14 (21.9)/12 (18.8)

0.046

22 (18.5)/16 (13.4)

14 (22.6)/11 (17.7)

0.525

Adjuvant chemotherapy

270 (89.1)

60 (93.8)

0.263

103 (86.6)

58 (93.5)

0.154